"Patience is a Super Power" - "The Money is in the waiting"

Thursday, August 7, 2025

Kraken Robotics - NATO Navy supplier is moving up the ladder with massive, undersea battery facility!

 


Technology for: NATO Navies, Energy companies, pipeline inspections, undersea exploration

Recent Developments

1. Massive SeaPower™ Battery Orders & Nova Scotia Expansion

  • Kraken secured $34 million in SeaPower battery orders from three clients, including a $31 million order—its largest yet—from a UUV defense provider, plus $3 million from two commercial clients.finance.yahoo.com+15

  • The company signed a lease and committed $10 million to establish a 60,000 sq ft battery production facility in Nova Scotia by late 2025. Once operational, capacity could nearly triple—approaching $200 million in annual battery output—and create around 200 advanced manufacturing jobs.Kraken Robotics+2ept.ca+2


2. Q1 2025 Financial Results & Forward Guidance

  • Revenue dropped 23% YoY to C$16.1 million, driven by a 42% decline in product revenue offset by a 38% surge in service revenue thanks to strong demand for Sub-Bottom Imager™ and Acoustic Corer™ services.GlobeNewswire+5Kraken Robotics+5Ocean Science & Technology+5

  • Gross margin improved sharply—from 44.8% to 62.7%—though Adjusted EBITDA dipped 32% to C$2.8 million (17.3% margin).Kraken Robotics+1

  • Cash position soared to C$58.3 million, up from C$1.5 million a year earlier, with working capital rising to C$94.6 million—providing robust liquidity for growth.Ocean Science & Technology+3

  • Kraken reaffirmed its 2025 guidance: projecting C$120 million–C$135 million in revenue and C$26 million–C$34 million in Adjusted EBITDA, with most of the year's gains expected in H2.Kraken Robotics+1

  • Key achievements since year-end included ~$45 million in new subsea battery orders


     $3 million in SAS orders, launching its KATFISH SAS service for offshore energy markets, and completing its 3D at Depth acquisition

    (Texas, Colorado, UK)
    .GlobeNewswire+8Kraken Robotics+8

3. $115 Million Bought-Deal Equity Financing

  • On July 7, 2025, Kraken closed a C$115 million bought-deal public offering, issuing 43.24 million shares at C$2.66 each (including over-allotment).Kraken Robotics+4

  • The raised capital is earmarked for accelerating strategic growth—such as funding acquisitions (especially in the US and Europe), bolstering the balance sheet for larger government and commercial contracts, and general corporate usage.Kraken Robotics+2

4. Board Strengthening with Defense Expertise

  • On June 4, 2025, Kraken appointed Kristin Robertson—a veteran with experience at RTX, Boeing, and defense strategy—as a new member of its Board of Directors, enhancing its governance and defense-industry insight.Ocean Science & Technology+3

5. LiDAR Subsidiary Reaches Milestone

  • Kraken’s recently acquired U.S, LiDAR firm, 3D at Depth, completed its 1,000th subsea metrology project for TotalEnergies, reflecting operational scale and service credentials.Kraken Robotics Science & Technology+6


6. Strong SAS Demand Continues

  • The company also reported over C$3 million in new Synthetic Aperture Sonar (SAS) orders. These systems are being integrated across small and medium UUVs in the Asia-Pacific, Europe, and North America, including a project with the University of Southern Mississippi’s Roger F. Wicker Center.GlobeNewswire+7



Strategic Summary

Focus AreaKey Insight
Financing & LiquidityC$115M raised, C$58M in cash, healthy working capital
Manufacturing ExpansionNova Scotia facility enhances battery output & logistics
Product & Service GrowthStrong SeaPower, SAS, LiDAR orders bolster pipeline
Corporate StrengtheningAdded board expertise and LiDAR operational scale
Forward PathwayWell-positioned for upcoming contract fulfillment in 2025+

Kraken Robotics continues to build strategic momentum—boosting its financial runway, expanding production, winning key orders, and deepening its defense-industry capabilities. It’s clearly accelerating toward becoming a global prime contractor in subsea defense and energy markets.

Ed Note:  We added to our position in PNG Today, August 7th, 2025

Wednesday, August 6, 2025

As silicon photonics products go mainstream in the Ai race, Toronto's POET Technologies Inc is a first mover!

 


An investment and business case for POET Technologies Inc. (NASDAQ: POET, TSXV: PTK), a Toronto‑based player in silicon photonics designed to meet explosive AI infrastructure demand:



🚀 1. Market Opportunity & Strategic Positioning

  • AI Datacenter Bottleneck: Data centers increasingly rely on optical connections for high bandwidth and low-power interconnects—traditional copper can’t keep up. POET’s silicon‑photonics platform addresses this critical need.TradingView+15AInvest+15StockAnalysis+15

  • Multibillion‑Dollar Upside: The addressable market for optical engines in AI infrastructure is projected to grow to $5.6 billion, expanding at ~22.5% CAGR through 2032.AInvest


🛠️ 2. Technology & Execution Catalysts

  • Teralight™ (1.6T optical engines) & Blazar™ light sources are key product lines targeting high-speed AI interconnects.arXiv+5AInvest+5AInvest+5

  • Optical Interposer™: The company’s integration of photonic and electronic devices into a single module earned industry recognition such as the Elite Score Award and AI Breakthrough Awards.SEC+3AInvest+3StockAnalysis+3

  • Manufacturing scale-up:


📈 3. Financials, Funding & Growth Trajectory

  • Pre‑revenue stage, but Q1 2025 showed early revenue (~$166,760) and a net income of $6.3 million—driven largely by non‑cash warrant gains.SEC+3AInvest+3AInvest+3

  • Capital base: Raised approximately US $40 million in Q1 and US $25 million in July 2025 public offerings—providing sufficient runway toward anticipated inflection points.AInvest+1StockAnalysis

  • Revenue inflection: POET expects to hit run-rate revenues between US $50–100 million in 2026 once Foxconn FIT begins volume production of its modules.SEC+12AInvest+12Seeking Alpha+12


📌 4. Investment Thesis & Potential Upside

  • Low current valuation / asymmetric upside: Market cap stands under US $500 million (~US $5.50/share), with a single-digit P/S multiple against potential large-scale sales.AInvest

  • Analysts from Northland raised the target to US $7, with earlier estimates between US $6–7.Wealthy Venture CapitalistAInvest

  • If POET captures even a modest slice of the high‑speed transceiver market, it could represent a “ten‑bagger” for patient investors.StockAnalysis+4Seeking Alpha+4AInvest+4


⚠️ 5. Risk Factors

FactorDescription
ExecutionDelays in scaling manufacturing at Malaysia facility or difficulties transitioning from samples to high‑volume production could defer revenue.
CompetitionEstablished players (Intel, Ayar Labs, others) are also targeting optical interconnects.
Financial riskContinued R&D and cash burn remain substantial; future financing may dilute shareholders.AInvestAInvest+1
Macroeconomic & cyclical riskAI infrastructure spending cycles, geopolitical tensions (China/US), and semiconductor downturns could dampen momentum.

🎯 6. Key Milestones to Track

  • Volume production ramp‑up at Foxconn FIT in H2 2025 and revenue delivery in 2026

  • Quarterly updates on shipments of 800G and 1.6T modules to hyperscalers or enterprise customers

  • Utilization and capacity of Malaysia manufacturing facility

  • Updates on partnerships (Lessengers, Adtran, etc.)

  • Operating cash flow trends and any further capital raises


✅ Investment Summary

  • POET Technologies sits at the convergence of advanced silicon photonics and surging demand for AI datacenter hardware.

  • Catalyst‑laden roadmap: technology awards, new manufacturing facilities, and partnerships positioning the company for scale in 2026.

  • Buy case: for long‑horizon investors (3–5 years), POET offers high-risk, high-reward upside—visibility on commercialization, strong IP, and low current valuation offer a compelling entry point.

  • Sell case: those cautious of execution risk or preferring revenue‑generating companies may find POET speculative at this juncture.

Tuesday, August 5, 2025

As IONQ prepares to report tomorrow, August 6th, progress is ongoing and there are some new developments!

 


Key Developments & Strategic Highlights

📆 Q2 2025 Earnings Coming Soon

  • IonQ is scheduled to report Q2 results after market close on August 6, 2025, with a call at 4:30 PM Eastern GuruFocusIonQ.

  • Analysts estimate ~$17.2M revenue and a −$0.27 EPS for the quarter, while full-year 2025 consensus stands at ~$84M in revenue and −$1.00 per share GuruFocus.

📈 Analyst Sentiment & Price Targets

  • IonQ shares recently traded near $40, down from earlier highs; one analysis shows an average one-year price target of $49.29, ranging from $30 to $70 GuruFocusTradingView.

  • Zacks issued a strong-buy suggestion, citing favorable analyst ratings drawn by institutional investor interest Yahoo FinanceZacks.

🚀 Sector Momentum

  • Following comments from Microsoft CEO Satya Nadella on July 31, quantum computing stocks rallied—IonQ jumped ~4%, reflecting positive sentiment around its future potential in cloud acceleration Investors.com.

🔧 Strategic Partnerships & Talent Expansion

  • IonQ is leveraging quantum-classical hybrid workflows in collaboration with Oak Ridge National Laboratory and the U.S. Department of Energy to optimize power-grid scheduling across generators—demonstrating real-world use cases for its Forte Enterprise 36‑qubit system IonQIonQ.

  • The company made key hires:

    • Marco Pistoia joined as SVP of Industry Relations, bringing expertise from JPMorgan Chase and IBM in quantum algorithms and QKD links Stock Titan.

    • Rick Muller was appointed VP of Quantum Systems; previously a leader at IARPA and DOE-focused labs, he’ll drive IonQ’s goal of reaching millions of qubits by 2030 Stock Titan.

🌏 Global Expansion & Ecosystem Builders

  • IonQ expanded presence in the APAC region via collaboration with Emergence Quantum in Australia—focusing on ASIC design and materials for next-gen ion-trap hardware Stock Titan.

  • Named the primary quantum partner for South Korea’s first National Quantum Computing Center, IonQ will supply high-end systems and hybrid computing infrastructure via KISTI-led programs Stock Titan.


🧠 Research & Technology Advances

⚛️ Neutrinoless Double‑β Decay Simulation

  • Researchers achieved the first real-time quantum simulation of lepton-number violation (neutrinoless double‑β decay) on IonQ’s Forte Enterprise system, using up to 36 qubits and error mitigation—a breakthrough in quantum nuclear physics arxiv.org.

🌐 IonQ’s Hardware Roadmap

  • IonQ’s portfolio now includes Harmony (retired), Aria (#AQ25), Forte, Forte Enterprise (#AQ36), and the upcoming Tempo system (target #AQ64) IonQ+1.


📊 Investor Implications

ThemeCommentary
Short-Term CatalystQ2 earnings on August 6 could move share price materially, especially against revised guidance.
Institutional & Analyst ConfidenceStrong analyst sentiment and rising endorsements from research outlets indicate resurgent investor interest.
Commercial TractionGovernment and national lab partnerships reflect real-world value and enterprise use case validation.
Technological LeadershipUnique QKD, hybrid simulation, and high-fidelity ion-trap systems help IonQ stay ahead.
Global Ecosystem FootprintStrategic collaborations across APAC and East Asia enhance regional market access and R&D reach.

🎯 Summary

  • As IonQ stands on the cusp of its Q2 earnings release and continues to build momentum through strategic hires, partnerships, and technical milestones, investor and industry confidence are aligning around its trajectory.

  • Institutional networks and expert endorsements are reinforcing belief in IonQ's roadmap toward fault-tolerant, high-qubit systems and practical quantum applications.

  • Near-term updates—especially around revenue progression, profit margins, and deals—will be crucial in shaping investor sentiment and market positioning.

ED Note:  

We continue to accumulate.  Our entry last year was around the $10 mark! Trading today at $41

Thursday, July 31, 2025

MP Materials has had a tremendous run in July as the REE fever rose. Going forward, there are others to consider as M&A candidates for MP

 


Based on current data (as of mid-2025), rare earth industry trends, government backing, stage of development, and market positioning, here are the top four REE-related companies most likely to increase significantly in value over the next year, ranked by risk-adjusted upside potential:


🥇 1. Ucore Rare Metals Inc. (TSXV: UCU / OTCQX: UURAF)

Why it could surge:

  • Constructing REE separation facility in Louisiana (RapidSX™ tech)—set to begin commissioning late 2025.

  • Strong U.S. government support via Department of Defense funding (DPA Title III).

  • Positioned to become first U.S.-based independent REE separator in decades.

  • Strategic role in breaking China’s REE monopoly.

Catalysts:

  • Facility commissioning, commercial offtake agreements, potential downstream partnerships.

Risk: Execution and funding dilution risk.


🥈 2. Ramaco Resources Inc. (NASDAQ: METC)

Why it could surge:

  • Already profitable from coal, providing internal capital for REE development.

  • Owns a major REE deposit (~1.7M tons TREO), pilot REE plant set for late 2025.

  • Strong cost discipline; low debt.

  • First U.S. company potentially transitioning from coal to REE production + metallurgy.

Catalysts:

  • Pilot plant progress, REE spin-out or joint ventures, metallurgical news.

Risk: REE development is early-stage; valuation still coal-centric.


🥉 3. American Rare Earths Ltd. (OTCQX: ARRNF / ASX: ARR)

Why it could surge:

  • Controls two of the largest undeveloped U.S. REE deposits (La Paz, AZ and Halleck Creek, WY).

  • Exploration results show world-scale tonnage and scalability.

  • Gaining visibility as a U.S. critical minerals supplier—potential acquisition target.

Catalysts:

  • Updated resource estimates, PEA release, government grants, U.S. defense interest.

Risk: No revenue, pre-PEA stage; high dilution potential.


🏅 4. Energy Fuels Inc. (NYSE American: UUUU)

Why it could surge:

  • Currently producing REEs (NdPr) from monazite at White Mesa Mill.

  • Also active in uranium and vanadium—diversified cash flow.

  • Working toward rare earth separation and metals production.

  • One of few North American producers already shipping REE concentrates.

Catalysts:

  • Rare earth oxide production ramp, long-term supply deals, uranium price spike.

Risk: Multi-commodity exposure adds complexity; commodity volatility.

Honorary mention:  Avalon (AVL.t) see...

nasdaq.com/press-release/avalon-advanced-materials-announces-28-increase-measured-and-indicated-mineral


News-Aug 1st... 

msn.com/en-us/money/markets/trump-administration-weighs-expanding-price-support-for-u-s-rare-earth-projects-reuters/ar-AA1JFWnQ?ocid=socialshare

🧭 Summary Table

RankCompanyTickerKey StrengthNear-Term CatalystsRisk Level
1️⃣Ucore Rare MetalsUCU / UURAFREE separation, U.S. gov't backingFacility launch, contractsModerate
2️⃣Ramaco ResourcesMETCProfitable, REE pivotPilot plant, REE newsModerate
3️⃣American Rare EarthsARRNFMassive U.S. depositsPEA, gov't interestHigh
4️⃣Energy FuelsUUUUAlready processing REEsREO output growthModerate 

Tuesday, July 29, 2025

Comprehensive Business & Investment Report: BiomX Inc. (NYSE: PHGE) bacteriophage (Phage) based therapies targeting chronic and resistant bacterial infections!

 



1. Executive Summary

BiomX Inc. is a clinical-stage biotechnology company pioneering in the development of bacteriophage-based therapies targeting chronic and resistant bacterial infections. The company operates a dual-platform strategy: engineered fixed-cocktail therapies and personalized phage treatments derived from its proprietary BOLT platform and its 2024 acquisition of Adaptive Phage Therapeutics (APT). 

BiomX is actively advancing its lead programs BX004 and BX211 for cystic fibrosis-related infections and diabetic foot osteomyelitis (DFO), respectively.

 With strong institutional and federal funding, multiple regulatory designations, and promising Phase 2 data, BiomX is well-positioned for growth and strategic partnerships or acquisition.


2. Business Model

BiomX develops phage therapies through discovery, clinical validation, and regulatory pathways, generating value by:

  • Advancing candidates to Phase 2/3 and licensing or partnering with larger pharma.

  • Leveraging personalized and fixed cocktail modalities for broad and niche indications.

  • Capitalizing on fast-track regulatory status and non-dilutive public funding.


3. Technology & Pipeline

BX004 (Cystic Fibrosis, Pseudomonas aeruginosa)

  • Fixed phage cocktail showing ~500-fold reduction in bacterial load in Phase 1b/2a.

  • Orphan Drug and Fast Track designations.

  • Phase 2b trial ongoing; topline results expected Q1 2026.

BX211 (Diabetic Foot Osteomyelitis, S. aureus)

  • Personalized phage therapy inherited from APT acquisition.

  • Phase 2 trial showed significant wound area and depth reductions (p < 0.05).

  • Supported by $40M U.S. Defense Health Agency grant.

  • Phase 2/3 planning underway.

Platform Technology: BOLT

  • AI and synthetic biology-driven platform for rapid phage discovery, matching, and engineering.


4. Strategic Partnerships & Clients

  • U.S. Defense Health Agency: $40M non-dilutive funding for BX211 trials.

  • Cystic Fibrosis Foundation: Financial and scientific support.

  • Acquisition of APT: Expanded pipeline, U.S. infrastructure, and personalized platform.


5. Key Investors (Institutional & Government)

  • Deerfield Management

  • OrbiMed

  • Nantahala Capital

  • AMR Action Fund

  • Cystic Fibrosis Foundation

  • U.S. Department of Defense / Defense Health Agency (DHA)

These investors reflect confidence in BiomX's mission and market potential, particularly amid rising concerns about antimicrobial resistance (AMR).


6. Financial Overview

  • Market Cap: ~$11M (as of July 2025)

  • Share Price: ~$0.43

  • Cash Reserves (Q1 2025): ~$21.2M

  • Net Loss (Q1 2025): ~$7.7M (vs $17.3M YoY)

  • Cash Runway: Through Q1 2026

  • Recent PIPE financing: $50M in March 2024; additional $12M in 2025


7. Competitive Landscape

Top Competitors:

  • Locus Biosciences: CRISPR-enhanced phages, partnered with BARDA and Janssen.

  • Armata Pharmaceuticals: Synthetic phages in clinical trials.

  • Intralytix: Commercial FDA-approved food safety phages.

  • Pherecydes Pharma, SNIPR Biome, PhagoMed: Emerging competitors.

BiomX Differentiators:

  • Dual strategy (engineered + personalized phage).

  • Phase 2 clinical data.

  • Institutional backing + government grants.

  • Proprietary discovery and engineering platform (BOLT).


8. M&A Prospects and Strategic Interest

Why BiomX Is a Target:

  • Clinical-stage programs addressing unmet needs (CF, DFO).

  • Military-backed therapy (BX211).

  • Proprietary phage platform.

  • Regulatory incentives and funding.

Potential Acquirers:

  • GSK, Merck, J&J, Pfizer: All are expanding in AMR and microbiome spaces.

  • Mid-cap biotech (e.g., Seres Therapeutics, Summit Therapeutics) seeking clinical-stage microbiome/phage pipelines.

Recent Precedent: BiomX acquired Adaptive Phage Therapeutics, indicating both consolidation momentum and capability to integrate external pipelines.


9. Investment Outlook & Milestones

MilestoneExpected TimingImportance
BX004 Phase 2b DataQ1 2026Major valuation catalyst
BX211 FDA meetingH2 2025Defines regulatory pathway
Potential Pharma PartnershipMid-2025+Catalyst for value, or prelude to acquisition
Cash runway assessmentLate 2025Determines need for funding or M&A

10. Valuation Scenarios

  • Bull Case: Positive data drives stock to analyst target of $15.50 (3,500% upside).

  • Base Case: Steady clinical progress + potential licensing = moderate upside.

  • Bear Case: Clinical or funding setbacks limit growth, though government backing cushions downside.


11. Conclusion

BiomX represents a high-risk, high-reward investment at the frontier of infectious disease therapeutics. With strong scientific platforms, strategic acquisition history, and increasing attention from government and institutional backers, the company is primed for either significant independent growth or acquisition. Upcoming clinical results and strategic partnerships will determine its trajectory through 2026.


Recommendation: For speculative investors with risk tolerance and interest in AMR/microbiome fields, BiomX offers compelling asymmetric upside, particularly ahead of its 2026 catalysts.